A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

Eligibility Criteria

• * Understand the study and agree to participate.
• * Be available for follow-up visits and contact for 12 months after the last study product is administered.
• * Be willing to undergo all study procedures.
• * Not be in another study unless approved by both study sponsors.
• * Be in good general health.
• * Have normal physical exam and lab results.
• * Agree to discuss HIV risk and prevention.
• * Have a certain minimum hemoglobin level (≥ 11.0 g/dL for women, ≥ 13.0 g/dL for men).
• * Have a white blood cell count within 2500 to 12,000/mm³.
• * Have a platelet count between 125,000 to 550,000/mm³.
• * Have an ALT level less than 2.5 times the upper limit of normal.
• * Have a serum creatinine level within 1.1 times the normal limit.
• * Have a serum calcium level of at least 8.5 mg/dL.
• * Have blood pressure within specified limits.
• * Test negative for HIV.
• * Test negative for Hepatitis C.
• * Test negative for Hepatitis B.
• * Women who can become pregnant must use effective contraception and test negative for pregnancy at enrollment.
• * Women who can become pregnant must agree not to seek pregnancy through alternative methods during the study period.
• * Breastfeeding or pregnant.
• * BMI is 40 or higher (exceptions can be made if you're in good health).
• * Diagnosed with diabetes (unless it's well-controlled Type 2 diabetes or gestational diabetes).
• * Received an investigational HIV vaccine or monoclonal antibodies.
• * Received a non-HIV investigational vaccine in the past year (exceptions exist for licensed or emergency-authorized vaccines).
• * Have an immune deficiency or are taking medications that impair immune response.
• * Received blood products or immunoglobulins within the last 16 weeks.
• * Received certain vaccines within 4 weeks before enrollment.
• * Received other vaccines within 14 days before enrollment.
• * Started allergy immunotherapy within the last year (stable therapy is okay).
• * Taken investigational research agents recently.
• * Had a serious reaction to any vaccine.
• * Have hereditary or acquired angioedema.
• * Had unexplained hives in the past year.
• * Have a bleeding disorder that would make study procedures risky.
• * Had seizures or taken seizure medication in the past 3 years.
• * Spleen has been removed or spleen doesn't work properly.
• * Active duty or reserve US military personnel.
• * Any serious health condition that could affect safety, rights, or ability to participate (including substance use, psychiatric disorders, recent suicide attempts, or cancer with potential recurrence).
• * Asthma that requires frequent or high-dose medication, emergency care, or multiple maintenance therapies.
• * History of certain immune-mediated medical conditions (mild, localized conditions may be okay).
• * Allergic to local anesthetics like Novocaine or Lidocaine.
• * History of difficult venous access or intravenous drug use.